Management of Cardiac Sarcoidosis Using Mycophenolate Mofetil as a Steroid-Sparing Agent
- 1 December 2021
- journal article
- research article
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 27 (12) , 1348-1358
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Long-Term Adverse Cardiac Outcomes in Patients With SarcoidosisJACC, 2020
- The Pathogenesis of Pulmonary Sarcoidosis and Implications for TreatmentChest, 2018
- Prognostic Value of Myocardial Scarring on CMR in Patients With Cardiac SarcoidosisJACC: Cardiovascular Imaging, 2017
- Cardiac SarcoidosisCirculation, 2015
- Cardiac Involvement in Sarcoidosis: Evolving Concepts in Diagnosis and TreatmentSeminars in Respiratory and Critical Care Medicine, 2014
- Comparison of Necropsy Findings in Patients With Sarcoidosis Dying Suddenly from Cardiac Sarcoidosis Versus Dying Suddenly from Other CausesThe American Journal of Cardiology, 2009
- SarcoidosisNew England Journal of Medicine, 2007
- Detection of Myocardial Involvement in Patients with Sarcoidosis Applying T2-Weighted, Contrast-Enhanced, and Cine Magnetic Resonance Imaging: Initial Results of a Prospective StudyJournal of Computer Assisted Tomography, 2002
- Clinical Characteristics of Patients in a Case Control Study of SarcoidosisAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Longitudinal Study of Chronic Sarcoidosis with Low‐Dose Maintenance Corticosteroid TherapyAnnals of the New York Academy of Sciences, 1986